Form D · Biotechnology
StimuSIL, Inc.
Wilmington, DE · CIK 0001939123
Offering snapshot reported Mar 7, 2025 · SEC filing
- Reported sold
- $600K Offering amount: $600K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 7, 2025 | Initial | $599,988 | No comparison | 2 | SEC filing |
| May 10, 2024 | Initial | $1,103,787 | No comparison | 7 | SEC filing |
| Sep 13, 2023 | Initial | $48,799 | No comparison | 1 | SEC filing |
| Aug 30, 2022 | Amendment | $574,998 | $5,264vs Aug 12, 2022 | 12 | SEC filing |
| Aug 12, 2022 | Initial | $569,734 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-540182
Source: Form D, filed Mar 7, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Abidin Gulmus | Director |
| Pablo Villalba | Director, Executive |
| Ana Villalba Villar | Director, Executive |
| Firat Yerlikaya | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2810 Church Street, Pmb 78535
Wilmington, DE, 19802
Wilmington, DE, 19802